sutures newsletter

PRODUCED BY AND FOR MEMBERS OF THE DEPARTMENT OF SURGERY October 2017 | Archived Issues

FDA Issues Recommendation Against Intraocular Vancomycin

The U.S. Food and Drug Administration (FDA) has issued a recommendation against the prophylactic use of intraocular vancomycin — alone or in a compounded drug combining multiple active ingredients — during cataract surgery because of the risk of hemorrhagic occlusive retinal vasculitis (HORV). HORV is a rare, potentially blinding postoperative complication that has been observed in dozens of patients who have received intraocular injections of vancomycin (anti-infective) formulations toward the end of otherwise uncomplicated cataract surgeries.

The FDA website has more information.